LY191704

LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1[1][2].

Product Specifications

CAS Number

[146117-78-4]

UNSPSC

12352005

Target

5 alpha Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/ly191704.html

Solubility

10 mM in DMSO

Smiles

CN1[C@@]2([H])[C@@](CCC1=O)([H])C3=CC=C(Cl)C=C3CC2

Molecular Formula

C14H16ClNO

Molecular Weight

249.74

References & Citations

[1]Farid NA, et al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996;24 (10) :1162-1165.|[2]Hirsch KS, et al. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci U S A. 1993;90 (11) :5277-5281.